{"title":"Hombre de 42 años con hepatitis B crónica, HBeAg positivo","authors":"M. Silva","doi":"10.1038/NCPGASTHEP0864","DOIUrl":"https://doi.org/10.1038/NCPGASTHEP0864","url":null,"abstract":"","PeriodicalId":51267,"journal":{"name":"Nature Clinical Practice. Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87490201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nuevas estrategias de tratamiento en la hepatitis B crónica","authors":"Morris Sherman","doi":"10.1038/NCPGASTHEP0863","DOIUrl":"https://doi.org/10.1038/NCPGASTHEP0863","url":null,"abstract":"","PeriodicalId":51267,"journal":{"name":"Nature Clinical Practice. Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86399853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tratamiento de la hepatitis B grave en el contexto del pre y pos trasplante hepático","authors":"Morris Sherman","doi":"10.1038/ncpgasthep0866","DOIUrl":"https://doi.org/10.1038/ncpgasthep0866","url":null,"abstract":"","PeriodicalId":51267,"journal":{"name":"Nature Clinical Practice. Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90941825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Emerging strategies for pegylated interferon combination therapy.","authors":"Eugene R Schiff","doi":"10.1038/ncpgasthep0691","DOIUrl":"https://doi.org/10.1038/ncpgasthep0691","url":null,"abstract":"<p><p>Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication. Several therapies are presently in development. Taribavirin hydrochloride (Viramidine, Valeant Pharmaceutical International, Singapore), a ribavirin prodrug, has shown promise, although the rate of sustained virologic response with this agent has been disappointing. The next generation of antivirals will consist of protease and polymerase inhibitors, a number of which are undergoing investigation, initially as monotherapy and subsequently in combination with pegylated interferon and ribavirin. Challenges include the prevention of recurrent HCV infection in liver-transplant recipients and development of a safe and effective HCV vaccine.</p>","PeriodicalId":51267,"journal":{"name":"Nature Clinical Practice. Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/ncpgasthep0691","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26499293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New paradigms in the management of hepatitis C virus co-infections.","authors":"Kenneth E Sherman","doi":"10.1038/ncpgasthep0692","DOIUrl":"https://doi.org/10.1038/ncpgasthep0692","url":null,"abstract":"<p><p>Liver disease has emerged as a major contributor to morbidity and mortality in patients with HIV infection. Hepatitis C virus (HCV) infection is a key element in the etiology of liver-associated injury in this population. Increased rates of fibrotic progression have been described and are mediated by alcohol use, the severity of immunosuppression, the use of antiretroviral therapy, and other factors. Large clinical trials have demonstrated the efficacy of treatment with pegylated interferon plus ribavirin and highlighted issues related to management of patients with HIV/HCV co-infection. Although treatment for HCV infection in this group remains a challenge, achievement of a sustained virologic response is feasible in approximately 35% of patients. Treatment must be individualized and attention must be paid to the potential for drug-drug interactions.</p>","PeriodicalId":51267,"journal":{"name":"Nature Clinical Practice. Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/ncpgasthep0692","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26499292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment of chronic hepatitis B","authors":"P. Pramita, R. Gani, A. Sulaiman","doi":"10.24871/6120059-15","DOIUrl":"https://doi.org/10.24871/6120059-15","url":null,"abstract":"Chronic hepatitis B is still a major health problem in Indonesia. Unfortunately, to date, treatment of chronic HBV (Hepatitis B virus) infection had not shown satisfactory Result. Monotherapy with alpha interferon or lamivudine have been widely used as treatment of chronic HBV. However, treatment response to Alpha interferon in Asian people was not satisfactory (15% - 20%), while monotherapy with lamivudine was not sufficient to eradicate HBV in chronically infected patients and commonly induce drug resistance. The occurrence of chronic hepatitis B resistant to lamivudine had encouraged development of newer agents such as adefovir, entecavir, emtricitabine and nucleoside analog. New therapeutic strategy using combination therapy should be considered if there is no sufficient response to monotherapy. Keywords : Treatment, chronic hepatitis B, combination therapy","PeriodicalId":51267,"journal":{"name":"Nature Clinical Practice. Gastroenterology & Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2005-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75572713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}